Platelet membrane wrapped drug loading porous nano particle and preparation method thereof

A nanoparticle and platelet technology, applied in the field of drug-loaded nanoparticles and their preparation, can solve the problems of low drug-degrading rate of PLGA nanoparticles, low immune effect and low immunogenicity of PLGA nanoparticles, and achieve excellent results. Biocompatibility, improved biocompatibility, low immunogenicity effect

Active Publication Date: 2019-03-08
DONGHUA UNIV
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The technical problem to be solved by the present invention is to provide a platelet membrane-wrapped drug-loaded porous nanoparticle and its preparation method to overcome the defects of low drug release rate based on PLGA nanoparticles and passive targeting and immune effects in the prior art
[0005] The materials used in the present invention have excellent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Platelet membrane wrapped drug loading porous nano particle and preparation method thereof
  • Platelet membrane wrapped drug loading porous nano particle and preparation method thereof
  • Platelet membrane wrapped drug loading porous nano particle and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0040] Example 1

[0041] (1) Add 105 mg PLGA to 10 mL dimethylformamide solution containing 2.9 mg EDC·HCl and 1.7 mg NHS, and activate for 0.5 h in an ice bath. When the temperature rises to room temperature, 9mg chitosan oligosaccharides are added and reacted for 48h under nitrogen protection. Then, the dialysis bag with a molecular weight cut-off of 7000 was dialyzed in PBS buffer with pH=7.4 for 3 days, and then freeze-dried to obtain CS-PLGA.

[0042] (2) Disperse the CS-PLGA, chitooligosaccharides, and PLGA obtained in step (1) in an aqueous solution with pH=5.0, 7.4, 8.6 to prepare a 0.5 mg / mL dispersion, and measure its Zeta potential respectively, as figure 2 As shown, when the pH changes from acidic to alkaline, the potential of CS-PLGA changes from positive to negative correspondingly, while the electrical properties of chitosan and PLGA do not change accordingly. The results showed that the chitosan oligosaccharides successfully bonded to PLGA and realized the potent...

Example Embodiment

[0043] Example 2

[0044] (1) Dissolve 10mg CS-PLGA and 1mg Bufalin in 1mL acetone, add them dropwise to 5mL TPGS 20% (w / v) deionized water at 800rpm speed, stir in the air for 3h, then put them into a vacuum drying oven , To remove residual acetone. Then it was washed three times with deionized water to remove TPGS, and finally resuspended with the same volume of deionized water to obtain porous structured drug-loaded nanoparticles. In order to set up a control, drug-loaded CS-PLGA / Bu nanoparticles without pore structure were prepared. The method was similar to the above method, except that the mixed acetone solution was added to deionized water without TPGS.

[0045] (2) Collect blood from the heart to obtain fresh blood from SD female rats, and add the anticoagulant blood to a centrifuge tube containing the separation solution (the volume ratio of anticoagulation blood to the separation solution is 1:2) and centrifuge at 300 g for 15 min. Pipet the first layer of platelet plas...

Example Embodiment

[0048] Example 3

[0049] (1) Take 2ml each of the CS-PLGA / Bu NPs dispersion, CS-pPLGA / Bu NPs dispersion and PLTM-CS-pPLGA NPs dispersion of Example 2 and put them into a dialysis bag with a molecular weight cut-off of 7000. Then they were immersed in 18 mL of pH=7.4 PBS buffer.

[0050] (2) Transfer the above-mentioned drug release system to a constant temperature shaker with a rotating speed of 100 rpm at 37°C for 48 h, and take 1 mL at 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, and 48 h, and measure it at 298 nm. Ultraviolet absorbance, and then re-supply 1mL PBS buffer under the same conditions, collect data and calculate the drug release.

[0051] The release curve of Bufalin in the three particles is as follows Image 6 Shown. After 48h, the cumulative drug release of CS-PLGA / BuNPs without pore structure was less than 20%. However, the cumulative release of CS-pPLGA / Bu NPs with porous structure is as high as 90%, which solves the problem of low release rate of PLGA-base...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a platelet membrane wrapped drug loading porous nano particle and a preparation method of the nano particle. The nano particle is prepared by modifying PLGA (poly (lactic-co-glycolic acid)) with chitosan oligosaccharide CS, loading Bufotalin and then wrapping with a platelet membrane. The preparation method comprises the steps of preparation of chitosan oligosaccharide modified PLGA, preparation of CS-pPLGA/Bu NPs, preparation of a platelet membrane fragment and preparation of PLTM-CS-pPLGA/Bu NPs. According to the method, the nano particle with the positively chargedsurface is prepared from CS modified PLGA; absorption of the negatively charged platelet membrane is facilitated by a layer-by-layer self-assembly manner; the stability of the nano particle is improved; and the prepared platelet membrane bionic coated porous nano particle is expected to achieve excellent biocompatibility, low immunogenicity and active cancer cell targeting ability, can actively deliver chemotherapeutics to tumor cells in a targeted manner, improves a treatment effect and has a very good practical value.

Description

technical field [0001] The invention belongs to the field of drug-loaded nanoparticles and a preparation method thereof, in particular to a platelet membrane-wrapped drug-loaded porous nanoparticle and a preparation method thereof. Background technique [0002] Poly(lactic-co-glycolic acid) (PLGA) has been widely used in the delivery of cancer chemotherapy drugs due to its good biocompatibility and biodegradability. However, due to its slow degradation time, high hydrophobicity and too dense nanoparticle structure, after the chemotherapy drugs carried by PLGA are injected into the body, the released drugs often cannot reach the effective dose to kill cancer cells. To solve this problem, porous PLGA-based nanoparticles were prepared using TPGS as a porogen, which enhanced the drug release rate (Zhu H, Chen H, Zeng X, et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA Nanoparticles for enhanced chemotherapy against multi-drug resistance [J]. Bioma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/51A61K47/34A61K47/36A61K47/46A61K31/585A61P35/00
CPCA61K9/5153A61K9/5161A61K9/5176A61K9/5192A61K31/585A61P35/00
Inventor 朱利民王海军谢晓田
Owner DONGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap